Latest fiscal year 2024 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2024, Ernexa Therapeutics Inc. reported revenue of $1M, up 755.9% year over year. Operating margin was -2693.1% and net margin -7652.7%, on a free-cash-flow margin of -2784.4% with capital expenditure at 63.4% of revenue. Every figure is computed directly from ERNA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2024 | $1M | -2693.1% | -7652.7% |
| FY2023 | $0M | -31080.9% | -31864.7% |
| FY2022 | $0M | n/a | n/a |
| FY2021 | n/a | n/a | n/a |
| FY2020 | $6M | -125.0% | -125.7% |
How does ERNA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.